Myomo SEC Filings

Myomo, Inc. director reports open-market share purchases on a Form 4. The reporting person bought 4,000 shares of Myomo common stock on 11/18/2025 at a price of $0.7345 per share in a single open-market transaction. On 11/19/2025, an additional 385 shares were purchased at a weighted average price of $0.765 per share. Following these transactions, the reporting person beneficially owned 75,748 shares directly and 479 shares indirectly through an immediate family member, for which beneficial ownership is disclaimed except to the extent of any pecuniary interest.

Myomo, Inc. received an amended Schedule 13G reporting that Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon collectively beneficially own 9.9% of Myomo’s common stock. The filing references 38,435,524 shares outstanding as of November 3, 2025.

The reported position reflects 3,790,788 shares of common stock and an additional 3,763,258 pre-funded warrants that are subject to a 9.99% “blocker”, which prevents exercises that would push ownership above that level. As a result, the warrants were not exercisable as of the event date, and the reporting persons indicate passive intent under Schedule 13G certifications.

Myomo, Inc. reported Q3 2025 results with revenue of $10.09 million, up from $9.21 million a year ago. Gross margin declined to 63.8% from 75.4% as higher material costs, increased manufacturing overhead tied to the new headquarters, and less capitalized overhead weighed on profitability. The quarter’s operating loss was $3.52 million, and net loss was $3.66 million (basic and diluted loss per share $0.09).

For the nine months, revenue reached $29.57 million versus $20.48 million last year, while net loss was $11.76 million. Cash and cash equivalents were $12.55 million at September 30, 2025. Operating cash outflow was $13.37 million year‑to‑date. On the balance sheet, the company had $1.0 million outstanding on its revolving credit line and $3.0 million under its term loan facility.

After quarter‑end, Myomo entered a new loan agreement providing up to $17.5 million in committed capital, with $12.5 million funded on November 4, 2025. Management states current cash and expected cash flows are sufficient to fund operations for at least the next twelve months. Shares outstanding were 38,435,524 as of November 3, 2025.

Myomo, Inc. entered a new senior secured Loan and Security Agreement with Avenue on November 4, 2025, providing committed term loans of up to $17.5 million. The company received $12.5 million at closing (Tranche 1), with up to $5.0 million available between November 4, 2026 and May 4, 2027, subject to no default. By mutual agreement, a discretionary tranche could add up to $10.0 million in 2027. The loans bear interest at 4.75% + WSJ prime (with a prime floor set on the closing date) and mature on June 1, 2029. Interest-only runs for 18 months after closing, extendable six months if Tranche 2 funds. The facility is secured by a senior lien on all assets, including IP.

Prepayment fees are 3.0%/2.0%/1.0% by anniversary, plus a 3.25% final payment fee at maturity or earlier prepayment. Covenants require at least $2.5 million of unrestricted cash, achieving ≥75% of trailing three‑month projected revenue, and limiting trailing six‑month cash burn to the greater of 150% of projected or $2.0 million. The lender may convert up to $3.0 million of Tranche 1 and $1.0 million of Tranche 2 into common stock at 120% of the warrant exercise price and holds a $1.0 million equity participation right. Myomo also issued a warrant to purchase up to $1,312,500 worth of common stock, exercisable at the lesser of $0.96 or the next bona fide equity round price before June 30, 2026, expiring November 4, 2030. A Q3 2025 results press release was furnished as Exhibit 99.1.

Myomo (MYO): Ownership update. Orin Hirschman and affiliated entities filed Amendment No. 4 to Schedule 13G reporting beneficial ownership of 523,000 shares of Myomo common stock, representing 1.3% of the class as of 09/30/2025. Mr. Hirschman has sole voting and dispositive power over these shares.

AIGH Capital Management LLC reports 0 shares. The filing indicates ownership of five percent or less of the class and includes a certification that the securities were acquired and are held in the ordinary course of business and not to influence control.

Myomo, Inc. (MYO) reporting person Paul R. Gudonis, who serves as Chief Executive Officer and a director, reported a gift of 10,000 shares of Myomo common stock on 09/09/2025. The transaction was coded as a disposition at $0 and the filer states it was a bona fide gift with no direct or indirect benefit to the reporting person. After the reported transfer, the reporting person beneficially owns 1,249,013 shares directly. The Form 4 was signed by an attorney-in-fact on 09/11/2025 and discloses the relationship of the reporting person to the issuer as CEO and director.

Myomo, Inc. director Thomas F. Kirk reported an open-market purchase of 50,000 shares of Myomo common stock on 08/25/2025 at an execution price of $1.15 per share. After the transaction the reporting person beneficially owns 474,420 shares, held directly. The Form 4 was signed by an attorney-in-fact on 08/26/2025. The filing states the purchases occurred in multiple lots at $1.15 per share and that the reporting party will provide transaction details to the SEC upon request. No derivative transactions, dispositions, or additional securities classes are reported.

Myomo, Inc. director Thomas F. Kirk reported open-market purchases of 50,000 shares of Myomo common stock on 08/18/2025 at an execution price of $1.10 per share (two transactions at $1.10 each). Following these purchases, Mr. Kirk beneficially owned 424,420 shares, held directly. The Form 4 was signed by an attorney-in-fact on 08/19/2025. The filing states the purchases were open-market trades and that details can be provided to the SEC upon request.